Treatment of Adenovirus Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Citations Over TimeTop 10% of 2001 papers

Abstract

Retrospective analysis of 303 patients who underwent allogeneic hematopoietic stem cell transplantation identified 35 (11.5%) with adenovirus infection. Among them, 22 received specific therapy. As first-line therapy, 18 were treated with intravenous ribavirin, 3 with cidofovir, and 1 with vidarabine. Moreover, 2 received donor leukocyte infusion in combination with ribavirin, and 1 received it after failing to respond to other therapies. Seven survived (31.8%; 3 of 13 who received ribavirin alone and 2 of 3 who received cidofovir). Among the 5 patients treated with combined strategies, 2 who received donor leukocyte infusions showed clearance of all symptoms. Acute graft-versus-host disease grade > or = 3 (P = .01) and a long delay between infection and treatment (P = .05) correlated with a greater risk of treatment failure. In conclusion, ribavirin and vidarabine are ineffective options, particularly for patients at who are high risk of acquiring disseminated adenovirus disease. Conversely, cidofovir or donor leukocyte infusions seem to be encouraging approaches if initiated early.

Related Papers

• → Real‐Time Blood Plasma Polymerase Chain Reaction for Management of Disseminated Adenovirus Infection(2003)188 cited
• → Successful cidofovir treatment of adenovirus-associated hemorrhagic cystitis and renal dysfunction after allogeneic bone marrow transplantation(2003)65 cited
• → G241(P) Cidofovir in severe adenovirus infection in an immunocompetent child: a case report and review of the literature(2020)1 cited
• → [Successful treatment with cidofovir for disseminated adenovirus infection accompanied by hemophagocytic syndrome and meningitis in an allogeneic hematopoietic stem cell transplantation recipient].(2021)1 cited
• → SUCCESSFUL TREATMENT OF SEVERE ADENOVIRUS INFECTION WITH INTRAVENOUS CIDOFOVIR IN A KIDNEY TRANSPLANTATION PATIENT(2008)